Thanigainathan Sivam, Abiramalatha Thangaraj
Neonatology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Neonatology, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
Cochrane Database Syst Rev. 2020 Jul 29;7(7):CD013392. doi: 10.1002/14651858.CD013392.pub2.
Uncertainty exists about the optimal point at which multi-component fortifier should be added to human milk for promoting growth in preterm infants. The most common practice is to start fortification when the infant's daily enteral feed volume reaches 100 mL/kg body weight. Another approach is to commence fortification earlier, in some cases as early as the first enteral feed. Early fortification of human milk could increase nutrient intake and growth rates but may increase the risk of feed intolerance and necrotising enterocolitis (NEC).
To assess effects on growth and safety of early fortification of human milk versus late fortification in preterm infants To assess whether effects vary based upon gestational age (≤ 27 weeks; 28 to 31 weeks; ≥ 32 weeks), birth weight (< 1000 g; 1000 to 1499 g; ≥ 1500 g), small or appropriate for gestational age, or type of fortifier (bovine milk-based human milk fortifier (HMF); human milk-based HMF; formula powder) SEARCH METHODS: We used the standard strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 8); OVID MEDLINE (R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Daily and Versions (R) (1946 to 15 August 2019); MEDLINE via PubMed (1 August 2018 to 15 August 2019) for the previous year; and the Cumulative Index to Nursing and Allied Health Literatue (CINAHL) (1981 to 15 August 2019). We searched clinical trials databases and reference lists of included studies.
We included randomised controlled trials that compared early versus late fortification of human milk in preterm infants. We defined early fortification as fortification started at < 100 mL/kg/d enteral feed volume or < 7 days postnatal age, and late fortification as fortification started at ≥ 100 mL/kg/d feeds or ≥ 7 days postnatal age.
Both review authors assessed trial eligibility and risk of bias and independently extracted data. We analysed treatment effects in individual trials, and we reported risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data, with respective 95% confidence intervals (CIs). We used the GRADE approach to assess the certainty of evidence.
We included two trials with a total of 237 infants. All participants were very low birth weight infants (birth weight < 1500 g). Early fortification was started at 20 mL/kg/d enteral feeds in one study and 40 mL/kg/d in the other study. Late fortification was started at 100 mL/kg/d feeds in both studies. One study used bovine milk-based fortifier, and the other used human milk-based fortifier. Meta-analysis showed that early fortification may have little or no effect on growth outcomes including time to regain birth weight (MD -0.06 days, 95% CI -1.32 to 1.20 days), linear growth (MD 0.10 cm/week, 95% CI -0.03 to 0.22 cm/week), or head growth (MD -0.01 cm/week, 95% CI -0.07 to 0.06 cm/week) during the initial hospitalisation period. Early fortification may have little or no effect on the risk of NEC (MD -0.01, 95% CI -0.07 to 0.06). The certainty of evidence was low for these outcomes due to risk of bias (lack of blinding) and imprecision (small sample size). Early fortification may have little or no effect on incidence of surgical NEC, time to reach full enteral feeds, extrauterine growth restriction at discharge, proportion of infants with feed interruption episodes, duration of total parenteral nutrition (TPN), duration of central venous line usage, or incidence of invasive infection, all-cause mortality, and duration of hospital stay. The certainty of evidence was low for these outcomes due to risk of bias (lack of blinding) and imprecision (small sample size). We did not have data for other outcomes such as subsequent weight gain after birth weight is regained, parenteral nutrition-associated liver disease, postdischarge growth, and neurodevelopmental outcomes.
AUTHORS' CONCLUSIONS: Available evidence is insufficient to support or refute early fortification of human milk in preterm infants. Further large trials would be needed to provide data of sufficient quality and precision to inform policy and practice.
关于在人乳中添加多成分强化剂以促进早产儿生长的最佳时机,目前仍存在不确定性。最常见的做法是当婴儿每日肠内喂养量达到100 mL/kg体重时开始强化。另一种方法是更早开始强化,在某些情况下最早在首次肠内喂养时就开始。人乳早期强化可能会增加营养摄入和生长速度,但可能会增加喂养不耐受和坏死性小肠结肠炎(NEC)的风险。
评估早产儿人乳早期强化与晚期强化对生长和安全性的影响。评估效果是否因胎龄(≤27周;28至31周;≥32周)、出生体重(<1000 g;1000至1499 g;≥1500 g)、小于胎龄或适于胎龄、或强化剂类型(基于牛乳的人乳强化剂(HMF);基于人乳的HMF;配方粉)而有所不同。
我们采用Cochrane新生儿组的标准策略,检索Cochrane对照试验中心注册库(CENTRAL;2019年第8期);OVID MEDLINE(R)及印刷版前的Epub、在研及其他未索引引文、每日和版本(R)(1946年至2019年8月15日);通过PubMed检索前一年的MEDLINE(2018年8月1日至2019年8月15日);以及护理及相关健康文献累积索引(CINAHL)(1981年至2019年8月15日)。我们检索了临床试验数据库和纳入研究的参考文献列表。
我们纳入了比较早产儿人乳早期强化与晚期强化的随机对照试验。我们将早期强化定义为在肠内喂养量<100 mL/kg/d或出生后年龄<7天时开始强化,将晚期强化定义为在喂养量≥100 mL/kg/d或出生后年龄≥7天时开始强化。
两位综述作者评估试验的合格性和偏倚风险,并独立提取数据。我们分析了各个试验中的治疗效果,对于二分法数据报告风险比(RR),对于连续数据报告平均差(MD),并给出各自的95%置信区间(CI)。我们采用GRADE方法评估证据的确定性。
我们纳入了两项试验,共237名婴儿。所有参与者均为极低出生体重儿(出生体重<1500 g)。一项研究中早期强化从肠内喂养量20 mL/kg/d开始,另一项研究中从40 mL/kg/d开始。两项研究中晚期强化均从喂养量100 mL/kg/d开始。一项研究使用基于牛乳的强化剂,另一项使用基于人乳的强化剂。荟萃分析表明,在住院初期,早期强化对包括恢复出生体重时间(MD -0.06天,95%CI -1.32至1.20天)、线性生长(MD 0.10 cm/周,95%CI -0.03至0.22 cm/周)或头围生长(MD -0.01 cm/周,95%CI -0.07至0.06 cm/周)等生长结局可能几乎没有影响。早期强化对NEC风险可能几乎没有影响(MD -0.01,95%CI -0.07至0.06)。由于存在偏倚风险(缺乏盲法)和不精确性(样本量小),这些结局的证据确定性较低。早期强化对手术性NEC发生率、达到完全肠内喂养的时间、出院时宫外生长受限、有喂养中断事件的婴儿比例、全胃肠外营养(TPN)持续时间、中心静脉置管使用时间、或侵袭性感染发生率、全因死亡率和住院时间可能几乎没有影响。由于存在偏倚风险(缺乏盲法)和不精确性(样本量小),这些结局的证据确定性较低。我们没有关于其他结局的数据,如恢复出生体重后的后续体重增加、肠外营养相关肝病、出院后生长和神经发育结局。
现有证据不足以支持或反驳对早产儿进行人乳早期强化。需要进一步开展大型试验,以提供质量和精度足够的数据,为政策和实践提供依据。